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1. Introduction 
Constitutional trisomy 21 or Down syndrome (DS) is the most common human genetic 
aneuploidy caused by the presence of all or part of an extra 21 chromosome. The incidence 
of DS is estimated at 1 per 700 births (Malinge et al., 2009) and is the most common genetic 
factor predisposing to childhood leukemia. People with DS present several clinical 
phenotypes, including cognitive impairment, craniofacial dysmorphy, gastrointestinal tract 
abnormalities, congenital heart defects, endocrine abnormalities, neuropathology leading to 
dementia and immunological defects. Concerning the hematopoietic system, children with 
DS frequently show abnormalities in platelet counts, macrocytosis and an increased 
prevalence of leukemia (Lange, 2000; Roizen & Amarose, 1993). 
2. Manifestations of leukemia in Down Syndrome 
The high frequency of leukemia in children with DS suggests that trisomy 21 is involved 
directly and functionally to the malignant transformation of hematopoietic cells. However, 
DS is not a classic genomic instability syndrome, since the overall risk of developing cancer, 
in particular solid tumors, including neuroblastoma and Wilms tumor, is lower in these 
people (Hasle, 2001; Malinge et al., 2009). 
Newborns with DS have a risk 10 to 20 times higher of developing acute leukemia (AL) 
when compared with the incidence rates of leukemia in the general child population 
(Hitzler et al., 2003). The AL in children with DS presents an intriguing relationship between 
the age at onset of disease and the subtype of leukemia cell. DS children older than 4 years 
have predominantly acute lymphoblastic leukemia (ALL), whose incidence is approximately 
20 times higher than in the general population. However the DS patients aged under 3 years 
are more likely to develop acute megakaryoblastic leukemia (AMKL), with an incidence  500 
times higher than in children without DS (Hitzler et al., 2003; Issacs, 2003; Lange, 2000; 
Malinge et al., 2009). 
The condition of patients with DS awakens, therefore, a special interest in studies on 
leukemogenesis not only by the high prevalence of AMKL, usually rare in the general 
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pediatric population, but also by another form of clonal proliferation called transient 
myeloproliferative disorder (TMD) which affects between 5 and 10% of newborns with DS. 
The TMD is a clonal disease characterized by accumulation of immature megakaryoblasts in 
fetal liver and peripheral blood, a picture indistinguishable from AL (Hitzler et al., 2003; 
Malinge et al., 2009; Pine et al., 2007; Rainis et al., 2003; Zipursky, 2003). It is unclear whether 
all AMKLs are preceded by TMD, since several TMD cases are underdiagnosed. One study 
suggests that the prognosis for AMKLs preceded by TMD is better than de novo AMKL 
(Klusmann et al., 2008). 
In contrast to AMKL, TMD usually evolves to spontaneous remission within the first three 
months of life and therefore is considered a pre-leukemic syndrome. This spontaneous 
remission can vary from 59 to 64% (Kanezaki et al., 2010; Massey et al., 2006). However, 
approximately 20% of children diagnosed with TMD will develop AMKL after 2 to 3 years 
of TMD spontaneous remission, which does not regress without chemotherapy (Malinge et 
al., 2009). 
The biological mechanism of TMD spontaneous remission is not clear. Holt et al. (2002) 
showed that telomerase activity was decreased at the beginning of congenital leukemia and 
suggested that this deficiency could explain the spontaneous regression. Furthermore, the 
factors underlying the transformation of the TMD "benign" status for "evil" in AMKL are 
unknown (Izraeli et al., 2007; Malkin et al., 2000; Rainis et al., 2003). 
In rare cases, the TMD is fatal due to poor prognostic factors such as liver fibrosis or liver 
dysfunction, manifested by jaundice, bleeding diathesis, fetal hydrops, cardiopulmonary 
failure, high white blood cell (WBC) and failure of spontaneous remission within the first 3 
months (Malinge et al., 2009; Massey et al., 2006; Pine et al., 2007; Shimizu et al., 2008). Most 
of these variants were found in all reports. However, the risk factors for the progression to 
AMKL remain unclear (Kanezaki et al., 2010). Three studies in the United States, Japan and 
Europe reported the natural course of TMD in 264 children with DS. These studies 
confirmed the transient course of this disease that usually resolved spontaneously within 
the first 3 months of life. However, these studies revealed that the disease is not benign, 
since early deaths have been reported in 15 to 20% of the cases (Klusmann et al., 2008; 
Massey et al., 2006; Muramatsu et al., 2008). Kanezaki et al. (2010) also reported early death 
in 24.2% of the DS patients with TMD. 
3. Mutations in GATA1 gene and leukemogenesis in Down Syndrome 
The GATA1 (globin transcription factor 1) gene located on the X chromosome in the region 
Xp11.23 encodes the GATA binding protein 1 (GATA-1) belonging to the family of 
transcription factors with zinc finger structural motifs for DNA binding. GATA-1 is essential 
for survival of erythroid progenitor cells and for proper maturation of megakaryocytes, so 
in this way this protein has an essential rule in the erythrocytic and megakaryocytic 
differentiation (Wechsler et al., 2002; Yu et al., 2002). 
The GATA1 gene is 6.857 kb long with 6 exons and an open reading frame of 1,239 
nucleotides starting in exon 2. The protein GATA-1 consists of 413 amino acids and 42.75 
kDa with an N-terminal transactivation domain and two zinc finger domains. These two 
fingers are functionally distinct and cooperate to achieve specific, stable DNA binding. The 
first finger (NF) is necessary only for full specificity and stability of binding, whereas the 
second one (CF) is required for DNA binding (Martin & Orkin, 1990, Shimizu et al., 2008). 
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GATA1 mutations prevent the synthesis of heavy chain of GATA-1 (translated from the first 
ATG codon of exon 2) but not the synthesis of truncated protein, with 330 amino acids and 
34.23 kDa called GATA-1s. GATA-1s is also expressed starting at codon 84 in exon 3 in 
consequence of an alternative translation initiation site or alternative splicing that eliminates 
exon 2. This truncated protein lacks the transactivation domain, but retains both zinc finger 
domains, as shown in figure 1. The function of GATA-1s is still quite unclear. Several 
experiments suggest that GATA-1s helps the megakaryocytic and erythrocyte differentiation 
(Weiss et al., 1997). However, studies of in vivo gene rescue indicated that only the 
endogenous GATA-1s expression would not be enough to restore definitive erythropoiesis 
unless this gene is hyper expressed (Shimizu et al., 2001). Even being detected both forms of 
GATA-1 in mouse embryonic tissue, their relative proportions vary during development, 
suggesting that the transcriptional activity of GATA1 can be modulated by the relative rate 
of the two forms (Calligaris et al., 1995). 
 
 
Fig. 1. Models for the expression of GATA-1 isoforms. The GATA-1 protein is translated 
from the GATA1 mRNA, whereas the GATA-1s protein can be translated either from the 
GATA-1 mRNA or from the alternative spliced GATA1s mRNA lacking exon 2. 
The analysis of megakaryocyte-specific knockdown of GATA1 in vivo has revealed a critical 
role for this factor in megakaryocytic development. Reduced expression (or complete 
absence) of GATA-1 in megakaryocytes leads to increased proliferation and deficient 
maturation as well as a reduced number of circulating platelets (Vyas et al., 1999; Wechsler 
et al., 2002). Mice harboring a heterozygous GATA1 knockdown allele frequently develop 
erythroblastic leukemia (Shimizu et al., 2004).  
Mutations in GATA1 gene are described in TMD as well as in AMKL, and occur mainly in the 
5’ end of the gene in exon 2, and less commonly in exon 3 (Xu et al., 2003). Mutations as 
insertions, duplications, deletions and point mutations, are responsible to abrogate splicing of 
exon 2 or to generate a stop codon prior to the alternative translational start codon at position 
84. According to Rainis et al. (2003), the most frequent mutations in TMD and AMKL were 
deletions and insertions in exon 2 of GATA1 corresponding to 65, 7% followed by 25.7% of 
point mutations and the remaining 8.6% is due to failure to identify the mutation.  
Mutations in GATA1 are frequently associated with TMD and occur in utero (Taub et al., 
2004). The true frequency of TMD is unknown because it is likely that a significant 
proportion of these patients are not routinely diagnosed (Malinge et al., 2009; Rainis et al., 
2003). Ongoing studies in Europe and North America combining screening for GATA1 
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mutations and examination of neonatal blood smears will present a more precise picture of 
the true incidence of TMD (Malinge et al., 2009). Pine et al. (2007) examined DNA from 
Guthrie cards of 585 DS infants, and reported that GATA1 mutations were detected in 3.8% 
of them. However, GATA1 mutations may have been missed in patients with minor 
preleukemic clones, subclonal mutations, low numbers of cells on Guthrie cards, or 
extramedullary TMD without circulating blasts. In addition, a significant higher frequency 
of GATA1 mutations in male newborns was observed. Malinge et al. (2009) presumed that it 
is likely that the frequency of TMD is not higher than 5% of DS newborns.  
Studies have shown that GATA1 mutations in TMD activate the proliferation of progenitor 
cells required to promote AMKL, featuring a multi-step disease. This process is likely to 
involve the participation of unidentified genes/proteins. These megakaryocytic progenitors 
quickly disappear after birth. Until now the molecular and cellular basis of this natural 
remission is unknown, but it may be related to changes in the hematopoietic 
microenvironment that occur during growth and neonatal development. Affected 
megakaryoblasts with additional genetic hits are probably subjected to clonal evolution, 
making them susceptible to malignant transformation to leukemic cells, leading to the 
development of AMKL (Shimizu et al., 2008) (figure 2). 
 
 
Fig. 2. A model for multi-step leukemogenesis in DS. The accumulation of hits (multiple 
genetic abnormalities) characterizes the evolution of TMD for AMKL.  
Somatic mutations in the N-terminus activation domain of GATA1 are found in most cases of 
TMD and AMKL, suggesting these mutations have a significant role in the process of 
leukemogenesis (Wechsler et al., 2002). GATA1 mutations with trisomy 21 may be sufficient to 
promote the expansion of transient megakaryoblasts seen in TMD (Mundschau et al., 2003).  
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The expression levels of GATA-1 isoforms are crucial for the proper development of 
erythroid and megakaryocytic cells and compromised GATA-1 expression is a causal factor 
in leukemia (Shimizu et al., 2008). These findings strongly suggest that the qualitative deficit 
of GATA-1 contributes to the genesis of TMD and AMKL (Kanezaki et al., 2010). The 
selection of mutations that retain GATA-1s may result in disruption of normal balance 
between GATA-1 and GATA-1s, which probably would be involved in regulating normal 
development of megakaryocytes (Izraeli et al., 2007), but pass to act as an oncogene directly 
in the presence of trisomy 21. Alternatively, GATA-1s may be required for survival of 
leukemic blasts and the oncogenic effect may be purchased by the loss of the heavy chain of 
GATA-1. Another possibility is that this type of mutation may reflect specific mechanisms of 
selection or generation of this mutation in the presence of trisomy 21 (Rainis et al., 2003).  
According some evidences the arising of AL is due to the cooperation between one class of 
mutations which interferes with differentiation (class II mutations) and another class which 
confers a proliferative advantage to cells (class I mutations) (Deguchi & Gilliland, 2002). It 
has been shown that high level expression of exogenous GATA-1 lacking the N-terminus 
induced differentiation rather than decreased the aberrant growth of GATA1-null 
megakaryocytes (Kuhl et al., 2005; Muntean & Crispino, 2005). This observation suggested 
that abundant GATA-1s functions like a class I mutation in TMD blasts. In contrast, 
reducing GATA-1 expression leads to differentiation arrest and aberrant growth of 
megakaryocytic cells (Vyas et al., 1999). The present data suggest that GATA-1s is expressed 
at very low levels in TMD blasts with GATA-1s low mutations. These levels may not be 
sufficient to provoke normal maturation. Together, these findings suggest that the low 
expression of GATA-1s might function like class II mutations in TMD blasts. Additional 
class I mutations or epigenetic alterations might be more effective in the development of 
leukemia in blast cells expressing GATA-1s at low levels (Kanezaki et al., 2010). 
GATA1 mutations have not been identified in normal children, in children with DS and 
other types of leukemia, or in acute myeloid leukemias (AML) of children without DS. 
Mutations restricted to leukemic clones were not detectable in samples in remission. They 
were therefore selected and acquired, probably because they granted a clonal advantage 
(Pine et al., 2007; Wechsler et al., 2002). 
Rainis et al. (2003) reported two patients with identical GATA1 mutations in TL and 
subsequently in AMKL, showing that the AMKL was originated from the clone of TMD. Thus, 
GATA1 is mutated in most patients with TMD, but that is not enough to generate leukemia 
after remission. Moreover, it has been reported that monozygotic twins that developed AMKL 
associated with acquired trisomy of chromosome 21 in blast cells have the same mutation that 
was not detected during remission. Because it was an identical mutation in the leukemic cells 
of twins, so it is likely that the mutation has occurred in one twin in utero and that his pre-
leukemic cells have migrated to the other twin by blood embryological anastomoses.  
Wechsler et al. (2002) analyzed the X chromosome inactivation in cell lysates from BM of 
women carrier from AMKL. Since the female leukemic cells showed the X chromosome 
inactivation due to monoclonality, and the mutant allele was detected only in leukemic cells, 
they predicted that the wild-type allele should be on the inactive X chromosome. As 
expected, only the truncated protein GATA-1s was observed. On the other hand Rainis et al. 
(2003) proposed that if there was no process of X chromosome inactivation, GATA1 
mutation would be involved in a higher frequency of patients with DS and TMD. Therefore, 
this inactivation of the GATA1 mutation is considered a key event for non-occurrence of the 
TMD transformation to AMKL (Rainis et al., 2003). 
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Ahmed et al. (2004) described for the first time multiple independent GATA1 mutations in 
four of 12 patients that developed AMKL, showing multiple GATA1 mutant clones in the 
same individual. In these patients, analysis of mutant clones by automated sequencing 
allowed to confirm that each clone contained a different mutation in GATA1. Interestingly, 
at the diagnosis of AMKL only one of the three mutations was present. The presence of 
these multiple GATA1 mutations suggests that mutations are a frequent event in 
hematopoietic cells of DS children. Using cell surface markers, Groet et al. (2005) showed the 
presence of several independent clonal expansions in different stages of megakaryocytic 
differentiation in a single patient with TMD. Probably this was due to independent clones 
that acquired the respective mutations in different stages of differentiation. 
GATA-1s is no different from wild type in their ability to bind to DNA and interact with its 
co-factor friend of GATA-1 (FOG-1), but shows a reduction in their ability to transcriptional 
activation since it was truncated to its activation domain N-terminal (Rainis et al., 2003; 
Wechsler et al., 2002).  
FOG-1 binds specifically to the NF zinc finger motif of GATA-1, and is expressed 
abundantly in erythroid and megakaryocytic cells (Crispino et al., 1999). FOG-1 is encoded 
by the gene ZPFM1 as a protein of 998 amino acids which contains nine zinc finger motifs, 
four of them (ZFS 1, 5, 6 and 9) mediate the interaction with GATA-1 (Fox et al., 1999; 
Muntean & Crispino, 2005). Studies using point mutations in GATA1 lead to a protein with a 
remarkable reduction of the affinity to FOG-1, but with ability of DNA binding, 
demonstrating that direct interaction FOG-1 and GATA-1 is required for normal 
erythropoiesis in vitro (Crispino et al., 1999).  
A missense mutation in the GATA1 gene was described in members without DS of a family 
affected with congenital dyserythropoietic anemia and thrombocytopenia. The 
megakaryocytes of these patients had similar changes in the megakaryocytes of mice 
deficient in expression of GATA-1 suggesting that the interaction GATA-1/FOG-1 is also 
crucial in late stages of megakaryopoiesis (Nichols et al., 2000). 
4. Other mutations associated with DS leukemia 
The occurrence of mutations in exon 2 of GATA1 in TMD suggests that there is cooperation 
between increased dosage of the gene or genes on chromosome 21 with the initiation of 
prenatal clonal proliferation of megakaryocytic precursors (Malinge et al., 2009).  
Based on numerous studies with mutations in GATA1 by several research groups, Malinge 
et al. (2009) concluded that the TMD and AMKL require both trisomy 21 and GATA1 
mutation but is not clear if only these alterations are enough to promote the TMD. 
Furthermore, the specific secondary mutations that promote the evolution of TMD to AMKL 
are still unknown. It has been identified cooperating mutations including JAK3, TP53, FLT3 
and JAK2 mutations whose frequencies are shown in table 1 (Malinge et al., 2009).  
The identification of activating mutations in tyrosine kinase genes in TMD and AMKL 
specimens has provided new insights into the evolution of AMKL. JAK3 mutations have been 
detected in a small but significant fraction of DS-leukemia samples. Among the mutations 
found, most were considered as gain of function. JAK3 was also found in the CMK cell line 
(cells that do not express GATA-1 wild type and are removed from patients with AMKL) 
inducing a lethal biphenotypic hematopoietic disorder in mice with features of AMKL 
(Walters et al., 2006). Other mutations in JAK3 have been proposed to be loss of function (De 
Vita et al., 2007). Additional experiments are necessary to determine how these different JAK3 
variants affect hematopoiesis and megakaryocyte development (Malinge et al., 2009). 
www.intechopen.com
 
Leukemogenesis in Down Syndrome 301 
 
Types of leukemia Mutated gene Localization Frequencies recorded 
 GATA1 Xp11.23 97,3% 
TMD JAK3 19p13.1 12,5% 
 TP53 17p13.1 7,7% 
 GATA1 Xp11.23 89,2% 
 JAK3 19p13.1 13,2% 
AMKL FLT3 13q12.2 5,7% 
 TP53 17p13.1 21,4% 
 JAK2 9p24.1 6,2% 
Table 1. Genetic abnormalities identified in leukemia associated SD. 
5. Trisomy 21 influence on hematopoiesis 
The functional contribution of the trisomy 21 in hematologic malignancies is supported by 
several observations such as the high incidence of leukemia in DS patients, the fact that 
TMD and AMKL blasts present trisomy 21 (even in children without DS), and that acquired 
trisomy or tetrasomy of chromosome 21 is frequently observed in blasts of different types of 
leukemia, including hyperdiploid ALL and de novo AML (Vyas & Crispino, 2007).  
It is assumed that the cells of DS complete or partial trisomy of Hsa21, approximately 33.7 
Mb, promote an overexpression of at least one of the 364 known genes, 31 antisense 
transcripts, and five different miRNAs (miR-99a, let-7c, miR-155, miR-125b-2, and miR-802), 
which could cooperate with the loss of GATA-1 in the pathogenesis of AMKL. Mutations in 
several genes on chromosome 21 have been identified in leukemia, and many of them 
recognized as encoding transcription factors acting at various stages of hematopoiesis. There 
should be contribution of genes present on chromosome 21 that cooperate with mutations of 
the GATA1 to cause leukemogenesis (Look, 2002; Malinge et al., 2009).  
The identification of the Down Syndrome Critical Region (DSCR) on the 21q22 band based 
in the genotype-phenotype correlations of partial trisomy in children suspected of having 
DS disclosed a list of genes potentially implicated in the clinical phenotype. However no 
specific genes have been certainly linked to the increased incidence of leukemia in DS. Few 
strong candidates include ERG, ETS2, and RUNX1 (Lyle et al., 2009; Malinge et al., 2009).  
Since the TMD is originated in a fetal liver progenitor and is restricted to children with DS 
(or to rare cases of acquired trisomy 21), it is presumed that trisomy 21 directly affects the 
development of hematopoietic cells during gestation. It has been shown that GATA1 
mutations can appear in 21-week-old embryos (Taub et al., 2004). To define the cellular 
context in which GATA1 mutations occur, two groups studied hematopoiesis in trisomy 21 
human fetal livers (FLs) (Chou et al., 2008; Tunstall-Pedoe et al., 2008). They found that 
although trisomy 21 did not alter the proportion of CD34+ and CD38- cells, trisomy 21 FLs 
showed a 2 to 3 fold increase of megakaryocyte erythroid progenitors (MEPs), which 
appeared to increase over time (35% at 16 weeks to 65% at 18 weeks). 
The functional perturbations induced by trisomy 21 probably induce a highly susceptible 
cellular environment to additional transformations such as GATA1 mutagenesis in TMD. 
The FL cell-based assay is a powerful tool to determine the specific Hsa21 genes that 
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participate in TMD. Preliminary quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) studies have shown that there are no significant differences in 
expression of ERG, ETS2, RUNX1, and SON, top-ranked candidate leukemia oncogenes, in 
trisomic versus euploid FLs (Chou et al., 2008; Tunstall-Pedoe et al., 2008). However, 
functional studies, such as knockdown of one or more of these candidates genes in FL 
progenitors followed by colony assays and transplantation experiments, are necessary to 
determine the requirements for these genes in leukemia (Malinge et al., 2009). 
6. Specific chromosome 21 genes in DS-associated leukemia 
Two microarray studies comparing AMKL versus non-DS AML have recently been reported 
(Bourquin et al., 2006; Ge et al., 2006) and 76 genes were described that discriminate 
between DS AMKL and non-DS. For example, genes encoding erythroid markers, 
glycophorin A and CD36, were found meaningly overexpressed in AMKL, as confirmed by 
immunophenotypic analysis of blasts (Langebrake et al., 2005).  
Analysis of the gene expression data also revealed that there is an overall increase in 
expression of chromosome 21 genes in AMKL, relative to non-DS AMKL. By gene set 
enrichment analysis, 47 Hsa21 genes, including BACH1, SON, C21orf66, and GABPA, 
contributed for this observed enrichment score, but the distinction between the 2 types of 
AMKL was not driven by differences in expression of chromosome 21 genes (Bourquin et 
al., 2006). By qRT-PCR and microarray analyses, Ge et al. (2006) found that 7 of 551 genes 
were up or down-regulated in AMKL relative to non-DS AMKL and not encoded by 
chromosome 21, including BST2, DUSP6, KRT18, and CD36. Differences in these two data 
might be explained by differences in the samples or different protocols and methods used to 
analyse the expression of the genes. 
6.1 Candidate leukemia oncogenes encoded by chromosome 21 
Of the genes on chromosome 21, several are compelling candidate leukemia oncogenes. Of 
these, four such candidates are RUNX1 (AML1), which encodes the heterodimeric partner of 
the complex of transcription factors denominated core-binding factor  (CBF), cooperates 
with GATA-1 during megakaryocytic differentiation, and the three ETS transcription factors, 
which are expressed and functionally involved in megakaryocytic differentiation and 
sensitivity to chemotherapy (ERG, ETS2, and GABPA) (Ge et al., 2008). It has been suggested 
that RUNX1 is involved in the AMKL, since mutations in the DNA-binding domain of RUNX1 
was identified in 5% of sporadic leukemia and in myeloid malignancies with acquired trisomy 
21 (Osato et al., 1999; Preudhomme et al., 2000). However, despite of the loss-of-function 
mutations in RUNX1 are associated with leukemia, it is not known how three copies of the 
chromosome 21 would promote tumorigenesis in DS (Izraeli, 2004). It is possible that cells with 
trisomy 21 express different levels of RUNX1 isoforms, affecting tumor development (Levanon 
& Groner, 2004). Despite of the fact that the total level of RUNX1 expression was lower in 
AMKL compared with non-DS AML, the differential expression of RUNX1 isoforms was 
indeed observed in human AMKL samples (Bourquin et al., 2006). In contrast, trisomy for 
Runx1 was found not to be required for the development of myeloproliferative disorder 
(MPD) in Ts65Dn mice (model used with partial trisomy 21) (Kirsammer et al., 2008). 
Furthermore, the Ts16 fetuses hematopoietic phenotype was not related with an increased 
ratio of Runx1 or an altered expression of its isoforms (Gjertson et al., 1999). 
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Inherited hypomorphic mutations in Runx1 cause low levels of expression in hematopoietic 
stem cells and result in the syndrome of thrombocytopenia with familial susceptibility to 
leukemia. Abnormalities in Runx1 were not detected in AMKL (Rainis et al., 2003). 
In different types of cancer, it has been shown that the ERG proto-oncogene is dysregulated, 
and its overexpression in AML samples with normal or complex karyotypes involving 
Hsa21 was observed (Baldus et al., 2004; Marcucci et al., 2005). An overexpression of ERG in 
human K562 cells that express both forms of GATA1 induced a switch in differentiation 
toward the megakaryocytic lineage and showed an increased expression of the early 
megakaryocytic markers, as CD41 and CD61 (Rainis et al., 2005). To confirm a role of ERG in 
late stages of megakaryopoiesis, Loughran et al. (2008), working with homozygous and 
heterozygous of mutant Erg mice, observed that the first one died in utero, in consequence 
of a defect in definitive hematopoiesis, and the second one showed thrombocytopenia with 
normal number of BM megakaryocytes.  
Overexpression of ETS2 has also been shown in several cancers, including AML (Baldus et 
al., 2004), and the amount of ETS2 transcripts are increased in both AMKL (DS or non-DS) 
(Ge et al., 2008). These facts and its involvement in the regulation of megakaryocytic genes 
suggest that ETS2 has an important role in TMD or AMKL. As same as for ERG, ETS2 
overexpression in K562 cells was found to promote a switch in differentiation from 
erythroid to megakaryocytic fate (Ge et al., 2008).  
The ETS family member GABPA is not considered an oncogene and its expression in the 
megakyocyte suggests that the GABPA protein has a role in early stages of megakaryocytic 
maturation (Pang et al., 2006). Recent studies have shown that GABPA directly affects the 
cell cycle by regulating the expression of genes required of DNA synthesis and degradation 
of cell-cycle inhibitors (Yang et al., 2007). Of Hsa21 genes, GABPA was one of the few whose 
expression is elevated in AMKL versus non-DS AML (Bourquin et al., 2006). 
6.2 miRNAs encoded by chromosome 21 
Hsa21 encode five miRNAs and overexpression of some of these has been observed in brain 
and heart tissues of people with DS and has been implicated in normal and pathologic 
hematopoiesis (Kuhn et al., 2008). For example, miR-99a is up-regulated during 
megakaryocytic differentiation of CD34+ cells, whereas miR-155 and let-7c are down-
regulated (Garzon et al., 2006). Notably, miR-155 has been linked to myeloproliferative and 
B-lymphoproliferative disorders (Garzon & Croce 2008; O’Connell et al., 2008). Studies have 
implicated miR-125b-2, which is overexpressed in TMD and AMKL samples compared with 
normal megakaryocytes, in the megakaryocytic leukemia of DS (Klusmann, 2007). 
Klusmann et al. (2010) showed that miR-125b-2 is an oncogene potentially involved in the 
pathogenesis of trisomy 21-associated leukemia. They demonstrated in mice and human 
that overexpression of miR-125b-2 led to specific hyperproliferation and enhanced self-
renewal capacity of megakaryocytic progenitor (MPs) and megakaryocytic/erythroid 
progenitors (MEPs), without affecting their normal differentiation. The miR-125b was highly 
expressed in AMKL blasts, whereas the identified target genes of miR-125b were down-
regulated. Thus, miR-125b-2 has a role in regulating megakaryopoiesis and in the 
pathogenesis of trisomy 21-associated TMD and AMKL, in cooperation with GATA1s. The 
miR-125b-2 exerts its oncogenic potential by at least two different mechanisms: blocking 
post-transcriptional miRNA processing through repression of DICER1 expression, and by 
inhibiting tumor suppressor genes, such as ST18. 
www.intechopen.com
 
Acute Leukemia – The Scientist's Perspective and Challenge 304 
7. Methods of leukemia diagnosis in DS 
The diagnosis of TMD usually occurs during the first weeks after birth and is observed as 
hydrops fetalis. The elevated blood count associated with hepatomegaly is the common 
symptom in an asymptomatic neonate. Infants with TMD can also display occasionally 
jaundice and bleeding diatheses, respiratory distress coupled with ascites, pleural effusion, 
signs of heart failure, and skin infiltrates. There is megakaryocytic infiltration and liver 
fibrosis, likely caused by excess cytokines secreted from the megakaryoblasts. The full 
clinical TMD may develop only at the second or third week of life. Laboratory tests are 
significant for either thrombocytosis or thrombocytopenia accompanied by elevated 
leukocytes with excess of blasts. The blood smear may show nucleated red cells, giant 
platelets and megakaryocytic fragments, and, most significantly, typical deeply basophilic 
blasts with blebs characteristic to megakaryocytic blasts. The differential diagnosis includes 
leukoerythroblastic reaction associated with prematurity, sepsis, or asphyxia. However, the 
blasts of TMD usually persist for several weeks, and GATA1 mutations are invariably found 
(Malinge et al., 2009). 
AMKL is preceded in 20 to 60% of cases by an indolent prephase of myelodysplasia (MDS), 
characterized by thrombocytopenia and dysplastic changes, BM aspiration is often dry, and 
fibrosis is detected in BM biopsy (Creutzig et al., 1996; Lange et al., 1998). This MDS can last 
several months or years before progressing to leukemia. In contrast to MDS in non-DS 
children, which requires stem-cell transplantation for cure, MDS in children with DS present 
a highly favorable response to chemotherapy alone (Lange et al., 1998). Therefore, Hasle et 
al. (2003) suggested that all cases of MDS and overt myeloid leukemia in DS, children 
should be classified as one disease entity, and referred to as ‘‘acute myeloid leukemia of 
Down syndrome’’ or ML DS. As this is a unique disease, it should be classified separately 
from other cases of AML in the WHO-classification. 
Immunophenotyping characterizes the hematopoietic lineage involved and their degree of 
maturation by monoclonal antibodies labeled with fluorochromes. Flow cytometry reveals 
that blasts are positive for CD34, CD33, CD41, CD61, glycophorin A, and often CD7 and 
CD36 (Langebrake et al., 2005, Massey et al., 2006). Savasan & Ravindranath (2003) observed 
that blasts of DS children with AMKL express CD36, in contrast to the low or no expression 
of CD36 in AML without DS. If 25% of blast cells are not detected, the diagnosis of AMKL 
can be given by the megakaryocytic markers CD41, CD61 and CD42a. The 
immunophenotype of the blasts in AMKL is generally similar to TMD, except that the 
percentage of CD34 cells may be lower in AMKL (Langebrake, 2005; Malinge et al., 2009).  
Pine et al. (2005) demonstrate the possibility of using specific GATA1 mutations already 
identified in the diagnosis of TMD or AMKL to monitor the size of the clone of leukemic 
cells over time with a sensitivity level (10-4 to 10-5) beyond the microscopic detection. The 
study confirmed that GATA1 mutations in TMD and AMKL can be used as clonal markers 
were suitable for measurement of minimal residual disease (MRD).  
This approach serves as a valuable tool in monitoring the spontaneous remission of TMD 
and in assessing response to treatment of AMKL subcytologic level. In addition, the MRD 
based GATA-1s mutations has been much in demand as a prognostic parameter for 
newborns with TMD. One may speculate, for example, that every group of newborns 
showing apparent remission of TMD can be divided into two subgroups: one in which the 
size of the clone of blasts in TMD after morphological remission continues to decline to 
become undetectable versus a second group, in which a clone of blasts in the TMD remains 
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detectable submicroscopic level. It is interesting to correlate these patterns of MRD kinetics 
in TMD with the probability of developing AMKL later (Hitzler & Zipursky, 2005). 
Additional copies of chromosome 8 and 21 in addition to the constitutional trisomy 21 are 
the most frequent in AMKL, and are found in approximately 10 to 15% for each 
chromosome. Cytogenetic findings associated with a high rate of relapse in non-DS AML, 
such as monosomy 7 and deletion 5/5q- also occur in DS patients but do not seem to have a 
negative impact on prognosis in the rare cases (Gamis et al., 2003, 2005; Rainis et al., 2003). 
The approach of molecular techniques including: PCR amplification of GATA1 exons 2 and 
3, followed by direct sequencing or analysis by denaturing high performance liquid 
chromatography (DHPLC), and cloning allow greater sensitivity and specificity of detection 
and have become essential for the identification of gene alterations in leukemias. The ability 
to detect mutations depends on the proportion of mutant cells in the sample. In general, for 
direct sequencing, approximately 20% of the sample has to have mutant cells. The sensitivity 
of DHPLC is higher at around 2 to 5%. Once a mutation has been identified, mutation-
specific probes and primers for mutation detection by qRT-PCR can be designed that allow 
for more sensitive detection of mutant cells, which may be used for MRD detection (Pine et 
al., 2005).  
Until recently, there were no reports on the expression levels of GATA-1s in TAM blasts, 
and the risk factors for the progression to AMKL. In 2010, Kanezaki et al. tested whether the 
spectrum of transcripts derived from the mutant GATA1 genes affects the expression levels. 
They classified the mutations according to the types of transcripts, and investigated the 
modalities of expression by in vitro transfection experiments using GATA-1 expression 
constructs harboring mutations. They have shown that the mutations altered the amount of 
mutant protein. Based on the evaluation of GATA-1s expression, the mutations were 
classified into two groups: high and low GATA-1s expression. Phenotypic analyses of 66 
TMD patients with GATA1 mutations revealed that GATA-1s low expression mutations 
were significantly associated with a high risk of progression to AMKL and lower counts of 
both WBC and blast cells. These results suggest that quantitative differences in mutant 
protein levels have significant effects on the phenotype of TMD. 
Nevertheless, neither mice nor humans with germline mutations expressing GATA-1s 
develop TMD or AMKL without trisomy 21 (Hollanda et al., 2006; Li et al., 2005). Therefore, 
the role of the trisomy 21 in the cellular transformation in AMKL seems to be fundamental 
(Klusmann et al., 2010). It remains unknown which factors on chromosome 21 cooperate 
with the oncogenic GATA-1s and which factors are involved in this transition from 
preleukemia to AMKL in only a part of these children (Kanezaki et al., 2010; Klusmann et 
al., 2007; Langebrake et al., 2006; Malinge et al., 2009).  
8. Treatment outcome  
DS children with AMKL have an excellent prognostic, with an approximately 80% cure rate, 
in relation to children without DS who develop AML (Arico et al.; 2008; Creutzig et al., 2005; 
Gamis et al., 2003; Rao et al., 2006; Taub et al., 1996). This outcome is possible on 
contemporary AML protocols which based in reducing treatment intensity regimens has 
considerably reduced the mortality rates in children with DS (Creutzig et al., 2005; Gamis et 
al., 2003; Whitlock et al., 2005; Zeller et al., 2005).  
AMKL blasts have shown hypersensitivity to varied chemotherapeutic drugs (Zwaan et al., 
2002). Probably the hypersensibility of the blasts to cytarabine (ARA-C) is due of the effect 
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of GATA1 mutations and Hsa21 on the levels of cytarabine-metabolizing enzymes (Ge et al., 
2005). ARA-C sensitivity is restricted to the leukemic population and may be caused by 
increased expression levels of the cystathionine-beta-synthase gene, which is located on 
Hsa21 (Taub et al., 2000). Despite of many patients respond favorably to a simple regimen 
including low-dose of ARA-C, this is not currently the standard of care. Since many 
problems have been occurred in treating of AMKL like toxic deaths, infections, and cardiac 
toxicity, thereby new and less-intensive protocols have been initiated in the United States 
and Europe (Creutzig et al., 2005; International Cooperative Pediatric AML Study Group 
Myeloid Leukemia DS 2006 [European Clinical Trials Database (EUDRACT) no. 2007-
006219-22]; Children’s Oncology Group: The Treatment of Down Syndrome Children with 
AML and MDS under the age of 4 Years [COG-AAML0431]; low dose cytarabine in treating 
infants with DS and TMD [COG-AAML0532]).  
Researchs in prospective clinical trials are trying to demonstrate whether treatment of TMD 
by low-dose cytarabine could prevent the arise of AMKL. Another related question to be 
clarified is whether treatment of clinically silent disease, identified by molecular detection of 
GATA1 mutations in patients who recovered from TMD, can prevent the future 
development of AMKL (Malinge et al., 2009). 
9. Conclusion 
In conclusion, many questions remain unanswered concerning the factors that contribute to 
the progression of TMD and AMKL in DS-patients. Progress in research to unravel these 
questions will improve diagnosis and treatment. Furthermore, ensuring the diagnosis of 
GATA1 mutations to the DS child to monitor the progression of the disease is essential to 
enable better clinical decision for the treatment regimen and, consequently, better quality of 
life to the patients. 
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